TY - JOUR
T1 - Difference in time-course of improvement in asthma control measures between budesonide and budesonide/formoterol
AU - Matsunaga, Kazuto
AU - Kawabata, Hiroki
AU - Hirano, Tsunahiko
AU - Sugiura, Hisatoshi
AU - Minakata, Yoshiaki
AU - Ichinose, Masakazu
N1 - Funding Information:
This work was partly supported by grant H24-Kibankenkyu(C)-22591057 from the Japanese Society for the Promotion of Science .
PY - 2013/4
Y1 - 2013/4
N2 - Combinations of inhaled corticosteroids (ICS) and inhaled long-acting beta2-agonists (LABA) have become widely used for the initiation of maintenance treatment for asthma. However, it has not been fully elucidated whether ICS/LABA alters the time-course of different control outcome measures in steroid-naive patients with asthma compared to the treatment with ICS alone.We compared the time-response in Asthma Control Questionnaire (ACQ), forced expiratory volume in 1 s (FEV1), exhaled nitric oxide fraction (FENO), and airway responsiveness to methacholine (PD200) between budesonide (BUD) and budesonide/formoterol (BUD/FM).BUD/FM therapy significantly improved the ACQ score at week 2 and week 4 (p < 0.01 and p < 0.05), and increased FEV1 and the methacholine threshold at week 8 and week 24 (all p < 0.05) compared to BUD alone. A logistic function model showed that the BUD/FM combination significantly improved ACQ, FEV1, FENO and PD200 at a faster rate than BUD over 24 weeks (p < 0.001 for ACQ, FEV1, PD200, and p < 0.05 for FENO, z-test). A significant variance in the time-response was also found in the outcomes of the two treatment groups (FENO and ACQ > FEV1 and PD200, p < 0.001, z-test).The present study provides evidence that ICS/LABA combination therapy results in a more rapid improvement in asthma symptoms, lung function, and airway inflammation compared to ICS monotherapy in steroid-naive patients with asthma.
AB - Combinations of inhaled corticosteroids (ICS) and inhaled long-acting beta2-agonists (LABA) have become widely used for the initiation of maintenance treatment for asthma. However, it has not been fully elucidated whether ICS/LABA alters the time-course of different control outcome measures in steroid-naive patients with asthma compared to the treatment with ICS alone.We compared the time-response in Asthma Control Questionnaire (ACQ), forced expiratory volume in 1 s (FEV1), exhaled nitric oxide fraction (FENO), and airway responsiveness to methacholine (PD200) between budesonide (BUD) and budesonide/formoterol (BUD/FM).BUD/FM therapy significantly improved the ACQ score at week 2 and week 4 (p < 0.01 and p < 0.05), and increased FEV1 and the methacholine threshold at week 8 and week 24 (all p < 0.05) compared to BUD alone. A logistic function model showed that the BUD/FM combination significantly improved ACQ, FEV1, FENO and PD200 at a faster rate than BUD over 24 weeks (p < 0.001 for ACQ, FEV1, PD200, and p < 0.05 for FENO, z-test). A significant variance in the time-response was also found in the outcomes of the two treatment groups (FENO and ACQ > FEV1 and PD200, p < 0.001, z-test).The present study provides evidence that ICS/LABA combination therapy results in a more rapid improvement in asthma symptoms, lung function, and airway inflammation compared to ICS monotherapy in steroid-naive patients with asthma.
KW - ACQ
KW - AHR
KW - Airflow limitation
KW - Airway hyperresponsiveness
KW - Airway inflammation
KW - Asthma Control Questionnaire
KW - BUD
KW - Exhaled nitric oxide
KW - FE
KW - FM
KW - PD
UR - http://www.scopus.com/inward/record.url?scp=84874569314&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84874569314&partnerID=8YFLogxK
U2 - 10.1016/j.pupt.2012.10.006
DO - 10.1016/j.pupt.2012.10.006
M3 - Article
C2 - 23123925
AN - SCOPUS:84874569314
VL - 26
SP - 189
EP - 194
JO - Pulmonary Pharmacology and Therapeutics
JF - Pulmonary Pharmacology and Therapeutics
SN - 1094-5539
IS - 2
ER -